Clinical Trial Update: Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of VARIVAX New Seed Process in children with varicella has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• Varivax (varicella vaccine (live attenuated))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Varicella | Phase 3 | Status: COMPLETED | Results posted: 2016-03-01